These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1087 related items for PubMed ID: 18385000

  • 1. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
    Fritsche TR, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
    [Abstract] [Full Text] [Related]

  • 2. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN, Sader HS, Fritsche TR, Pottumarthy S.
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
    Pillar CM, Aranza MK, Shah D, Sahm DF.
    J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
    [Abstract] [Full Text] [Related]

  • 4. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS, Fritsche TR, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
    [Abstract] [Full Text] [Related]

  • 5. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
    Fritsche TR, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
    [Abstract] [Full Text] [Related]

  • 6. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
    Jones ME.
    Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
    [Abstract] [Full Text] [Related]

  • 7. Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study.
    Rossolini GM, Dryden MS, Kozlov RS, Quintana A, Flamm RK, Läuffer JM, Lee E, Morrissey I, CLASS Study Group.
    J Antimicrob Chemother; 2011 Jan; 66(1):151-9. PubMed ID: 21051375
    [Abstract] [Full Text] [Related]

  • 8. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS, Jones RN, Dowzicky MJ, Fritsche TR.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [Abstract] [Full Text] [Related]

  • 9. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [Abstract] [Full Text] [Related]

  • 10. Antimicrobial activity of ceftobiprole against gram-negative and gram-positive pathogens: results from INVITA-A-CEFTO Brazilian study.
    Cereda RF, Azevedo HD, Girardello R, Xavier DE, Gales AC, INVITA-A-CEFTO Brazilian Study Group.
    Braz J Infect Dis; 2011 Jul; 15(4):339-48. PubMed ID: 21861004
    [Abstract] [Full Text] [Related]

  • 11. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).
    Fritsche TR, Sader HS, Stillwell MG, Jones RN.
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):440-6. PubMed ID: 19302928
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA, Jones RN, Leeds JA, Denys G, Sader HS, Fritsche TR.
    J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
    [Abstract] [Full Text] [Related]

  • 16. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).
    Fritsche TR, Stilwell MG, Jones RN.
    Clin Microbiol Infect; 2005 Dec; 11(12):974-84. PubMed ID: 16307551
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
    Biedenbach DJ, Jones RN.
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.